🔴 Kura Oncology is trading 10.63% down with no confirmed catalyst

Kura Oncology is trading at $8.83, down 10.63%, with the cause of the November 4 decline unclear.

• The company announced ASH presentations, including first combination data, but reporting does not link the news to the decline.
• The move came despite gains in the supplied market and biotech sector, so broad-market weakness does not explain it.
• Third-quarter results are scheduled for November 10.